Figure 1.

Cytotoxic effects of 18β-Gly on human lung cancer cells. (A) A549, NCI-H23, and NCI-H460 lung cancer cells were treated with different concentrations of 18β-Gly (10, 20, 30, 40, and 50 μM) for 24 h, after which their cell viabilities were determined by the CCK-8 assay. (B) IMR-90, GES-1, and 293T normal cells were treated with different concentrations of 18β-Gly (10, 20, 30, 40, and 50 μM) for 24 h, after which their cell viabilities were determined by the CCK-8 assay. (C) A549, NCI-H23, and NCI-H460 cells were treated at different time points (6, 12, 24, and 36 h) with IC₅₀ of 18β-Gly, after which their cell viabilities were determined by the CCK-8 assay. (D) IMR-90, GES-1 and 293T cells were treated at different time points (6, 12, 24, and 36 h) with IC₅₀ of 18β-Gly, after which their cell viabilities were determined by the CCK-8 assay. Data are expressed as the means ± SDs. *P < 0.05, **P < 0.01, ***P < 0.001 vs control.